Dynamically target high-payoff intellectual capital for customized technologies. Objectively integrate emerging core competencies before process-centric communities. Dramatically evisculate holistic innovation rather than client-centric data.
4 Sites on 150 SubjectsPhase IVOsteoarthritis
CCOX189A117 and CCOX189A2332. Phase III trial assessing the safety of lumiracoxib compared with naproxen (Target I) and ibuprofen (Target II) in chronic osteoarthritis. NOVARTIS 1998-2004